128 related articles for article (PubMed ID: 26464352)
1. Phase 2 trial of the topoisomerase II inhibitor, amrubicin, as second-line therapy in patients with metastatic urothelial carcinoma.
Galsky MD; Hahn NM; Wong B; Lee KM; Argiriadi P; Albany C; Gimpel-Tetra K; Lowe N; Shahin M; Patel V; Tsao CK; Oh WK
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1259-65. PubMed ID: 26464352
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer.
Ettinger DS; Jotte R; Lorigan P; Gupta V; Garbo L; Alemany C; Conkling P; Spigel DR; Dudek AZ; Shah C; Salgia R; McNally R; Renschler MF; Oliver JW
J Clin Oncol; 2010 May; 28(15):2598-603. PubMed ID: 20385980
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of amrubicin for second-line treatment of advanced non-small cell lung cancer: results of the West Japan Thoracic Oncology Group trial (WJTOG0401).
Kaneda H; Okamoto I; Hayashi H; Yoshioka H; Miyazaki M; Kudoh S; Kimura T; Sugiura T; Sawa T; Takeda K; Iwamoto Y; Satouchi M; Akita K; Saito H; Goto I; Shibata K; Fukuoka M; Nakagawa K;
J Thorac Oncol; 2010 Jan; 5(1):105-9. PubMed ID: 19884859
[TBL] [Abstract][Full Text] [Related]
4. Phase I/II study of amrubicin, a novel 9-aminoanthracycline, in patients with advanced non-small-cell lung cancer.
Sugiura T; Ariyoshi Y; Negoro S; Nakamura S; Ikegami H; Takada M; Yana T; Fukuoka M
Invest New Drugs; 2005 Aug; 23(4):331-7. PubMed ID: 16012792
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of amrubicin (SM-5887), a synthetic 9-aminoanthracycline, as first line treatment in patients with metastatic or unresectable soft tissue sarcoma: durable response in myxoid liposarcoma with TLS-CHOP translocation.
Gupta S; Gouw L; Wright J; Chawla S; Pitt D; Wade M; Boucher K; Sharma S
Invest New Drugs; 2016 Apr; 34(2):243-52. PubMed ID: 26897615
[TBL] [Abstract][Full Text] [Related]
6. Multicenter phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer (Study 1): West Japan Thoracic Oncology Group (WJTOG) trial.
Sawa T; Yana T; Takada M; Sugiura T; Kudoh S; Kamei T; Isobe T; Yamamoto H; Yokota S; Katakami N; Tohda Y; Kawakami A; Nakanishi Y; Ariyoshi Y
Invest New Drugs; 2006 Mar; 24(2):151-8. PubMed ID: 16502350
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of amrubicin as a third or later line of chemotherapy for advanced non-small cell lung cancer.
Igawa S; Sasaki J; Ishihara M; Otani S; Maki S; Hiyoshi Y; Kasajima M; Katono K; Takakura A; Masuda N
Chemotherapy; 2013; 59(2):99-105. PubMed ID: 24021914
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of amrubicin at a dose of 45 mg/m2 in patients with previously treated small-cell lung cancer.
Asao T; Nokihara H; Yoh K; Niho S; Goto K; Ohmatsu H; Kubota K; Yamamoto N; Sekine I; Kunitoh H; Fujiwara Y; Ohe Y
Jpn J Clin Oncol; 2015 Oct; 45(10):941-6. PubMed ID: 26232449
[TBL] [Abstract][Full Text] [Related]
9. Amrubicin monotherapy for elderly patients with previously treated lung cancer.
Nakao M; Oguri T; Suzuki T; Kunii E; Tomita Y; Iwashima Y; Miyazaki M; Maeno K; Sato S; Ueda R
Intern Med; 2010; 49(17):1857-62. PubMed ID: 20823645
[TBL] [Abstract][Full Text] [Related]
10. Amrubicin as second- or third-line treatment for women with metastatic HER2-negative breast cancer: a Sarah Cannon Research Institute phase 1/2 trial.
Yardley DA; Raefsky E; Hainsworth JD; Burris HA; Priego V; Inclan A
Breast Cancer Res Treat; 2014 Dec; 148(3):535-40. PubMed ID: 25374098
[TBL] [Abstract][Full Text] [Related]
11. [Late phase II clinical study of amrubicin hydrochloride, a novel synthetic anthracycline derivative anticancer agent, for malignant lymphoma].
Akutsu M; Kano Y; Ogawa M; Miura A; Hirano M; Masaoka T; Tatsumi N
Gan To Kagaku Ryoho; 2001 Nov; 28(12):1867-76. PubMed ID: 11729479
[TBL] [Abstract][Full Text] [Related]
12. Amrubicin as second-line and beyond treatment for platinum-refractory advanced thymic carcinoma.
Hirai F; Seto T; Yamanaka T; Toyozawa R; Inamasu E; Kojo M; Toyokawa G; Morodomi Y; Shiraishi Y; Takenaka T; Yamaguchi M; Takenoyama M; Ichinose Y
Jpn J Clin Oncol; 2013 Oct; 43(10):1018-22. PubMed ID: 23917962
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer.
von Pawel J; Jotte R; Spigel DR; O'Brien ME; Socinski MA; Mezger J; Steins M; Bosquée L; Bubis J; Nackaerts K; Trigo JM; Clingan P; Schütte W; Lorigan P; Reck M; Domine M; Shepherd FA; Li S; Renschler MF
J Clin Oncol; 2014 Dec; 32(35):4012-9. PubMed ID: 25385727
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcome of amrubicin therapy according to the prior chemotherapy sensitivities of extensive small cell lung cancer.
Mitsuoka S; Kudoh S; Kimura T; Yoshimura N; Tanaka H; Suzumura T; Umekawa K; Nagata M; Ueda T; Hirata K
Osaka City Med J; 2011 Dec; 57(2):59-66. PubMed ID: 22443079
[TBL] [Abstract][Full Text] [Related]
15. Phase I and pharmacokinetic study of amrubicin, a synthetic 9-aminoanthracycline, in patients with refractory or relapsed lung cancer.
Okamoto I; Hamada A; Matsunaga Y; Sasaki J; Fujii S; Uramoto H; Yamagata H; Mori I; Kishi H; Semba H; Saito H
Cancer Chemother Pharmacol; 2006 Feb; 57(3):282-8. PubMed ID: 16028099
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301.
Onoda S; Masuda N; Seto T; Eguchi K; Takiguchi Y; Isobe H; Okamoto H; Ogura T; Yokoyama A; Seki N; Asaka-Amano Y; Harada M; Tagawa A; Kunikane H; Yokoba M; Uematsu K; Kuriyama T; Kuroiwa Y; Watanabe K;
J Clin Oncol; 2006 Dec; 24(34):5448-53. PubMed ID: 17135647
[TBL] [Abstract][Full Text] [Related]
17. Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group.
Bamias A; Aravantinos G; Deliveliotis C; Bafaloukos D; Kalofonos C; Xiros N; Zervas A; Mitropoulos D; Samantas E; Pectasides D; Papakostas P; Gika D; Kourousis C; Koutras A; Papadimitriou C; Bamias C; Kosmidis P; Dimopoulos MA;
J Clin Oncol; 2004 Jan; 22(2):220-8. PubMed ID: 14665607
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of amrubicin hydrochloride and cisplatin in patients previously treated for advanced non-small cell lung cancer.
Ikeda J; Maruyama R; Okamoto T; Shoji F; Wataya H; Ichinose Y
Jpn J Clin Oncol; 2006 Jan; 36(1):12-6. PubMed ID: 16418184
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of single agent amrubicin in patients with previously treated advanced thymic malignancies.
Hellyer JA; Gubens MA; Cunanan KM; Padda SK; Burns M; Spittler AJ; Riess JW; San Pedro-Salcedo M; Ramchandran KJ; Neal JW; Wakelee HA; Loehrer PJ
Lung Cancer; 2019 Nov; 137():71-75. PubMed ID: 31557562
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of amrubicin and carboplatin for previously untreated patients with extensive-disease small cell lung cancer.
Ikeda T; Fukuda M; Nakamura Y; Kinoshita A; Senju H; Nakano H; Kitazaki T; Ogawara D; Taniguchi H; Motoshima K; Yamaguchi H; Nakatomi K; Shimada M; Nagashima S; Tsukamoto K; Kohno S;
Cancer Chemother Pharmacol; 2014 Sep; 74(3):497-502. PubMed ID: 25034978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]